TECX Key Statistics, Chart & Performance
The current stock price of TECX is 18.84 USD. In the past month the price decreased by -3.68%. In the past year, price decreased by -59.69%.
TECX Technical Analysis
TECX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TECX. While TECX seems to be doing ok healthwise, there are quite some concerns on its profitability.
TECX Financial Highlights
Over the last trailing twelve months TECX reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS increased by 60.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.3% | ||
| ROE | -25.16% | ||
| Debt/Equity | 0 |
TECX Forecast & Estimates
15 analysts have analysed TECX and the average price target is 81.47 USD. This implies a price increase of 332.44% is expected in the next year compared to the current price of 18.84.
TECX Ownership
TECX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.87 | 382.02B | ||
| AMGN | AMGEN INC | 15.71 | 185.02B | ||
| GILD | GILEAD SCIENCES INC | 15.76 | 160.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.56 | 117.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 78.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.59 | 48.28B | ||
| INSM | INSMED INC | N/A | 33.34B | ||
| NTRA | NATERA INC | N/A | 33.51B | ||
| BIIB | BIOGEN INC | 10.31 | 25.32B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.8 | 20.23B | ||
| INCY | INCYTE CORP | 16.3 | 20.55B |
Related stock screener links
About TECX
Company Profile
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Company Info
TECTONIC THERAPEUTIC INC
490 Arsenal Way, Suite 210
Watertown MASSACHUSETTS US
Employees: 51
Phone: 13396663320
TECTONIC THERAPEUTIC INC / TECX FAQ
What does TECX do?
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Can you provide the latest stock price for TECTONIC THERAPEUTIC INC?
The current stock price of TECX is 18.84 USD. The price decreased by -1.36% in the last trading session.
Does TECTONIC THERAPEUTIC INC pay dividends?
TECX does not pay a dividend.
How is the ChartMill rating for TECTONIC THERAPEUTIC INC?
TECX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is TECX stock listed?
TECX stock is listed on the Nasdaq exchange.
What is the market capitalization of TECX stock?
TECTONIC THERAPEUTIC INC (TECX) has a market capitalization of 352.68M USD. This makes TECX a Small Cap stock.
When does TECTONIC THERAPEUTIC INC (TECX) report earnings?
TECTONIC THERAPEUTIC INC (TECX) will report earnings on 2026-03-18, after the market close.